Por favor, use este identificador para citar o enlazar este ítem:
http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2025| Título : | A comparison of oral ondansetron syrup or intravenous ondansetron loading dose regimens given in combination with dexamethasone for the prevention of nausea and emesis in pediatric and adolescent patients receiving moderately/highly emetogenic chemotherapy |
| Creador: | White L. |
| Nivel de acceso: | Open access |
| Palabras clave : | Administración Oral Adolescente Antieméticos - administración & dosificación Antineoplásicos - efectos adversos Antineoplásicos - uso terapéutico Niño Preescolar Dexametasona - administración & dosificación Quimioterapia Combinada Femenino Humanos Lactante Infusiones Intravenosas Masculino Náusea - inducido químicamente Náusea - prevención & control Neoplasias - tratamiento farmacológico Ondansetrón - administración & dosificación Resultado del Tratamiento Vómitos - inducido químicamente Vómitos - prevención & control Administration, Oral Adolescent Antiemetics - administration & dosage Antineoplastic Agents - adverse effects Antineoplastic Agents - therapeutic use Child Child, Preschool Dexamethasone - administration & dosage Drug Therapy, Combination Female Humans Infant Infusions, Intravenous | Male Nausea - chemically induced Nausea - prevention & control Neoplasms - Drug therapy Ondansetron - administration & dosage Treatment Outcome Vomiting - chemically induced Vomiting - prevention & control Chemotherapy; Nausea; Ondansetron; Oral syrup; Vomiting |
| Descripción : | This double-blind, parallel-group, multicenter study compared the efficacy and safety of intravenous (IV) ondansetron with oral syrup ondansetron plus oral dexamethasone in the prevention of nausea and emesis in pediatric patients receiving moderately/highly emetogenic chemotherapy. On each day of chemotherapy, patients were administered ondansetron 5 mg/m2 IV and placebo syrup orally (n = 215) or ondansetron 8 mg syrup orally and placebo IV (n = 223) plus dexamethasone 2-4 mg PO. Ondansetron 4 mg syrup PO was administered twice daily for 2 days following the cessation of chemotherapy. Complete or major control of emesis was obtained in 89% patients in the IV group and 88% patients in the oral syrup group during the worst day of chemotherapy treatment (90% CI: -6, 4) and in 85% and 82% patients, respectively, during the worst day of the study period (90% CI: -8, 3). Intravenous or oral syrup ondansetron plus dexamethasone was well tolerated and effective in preventing chemotherapy-induced emesis in pediatric patients. |
| Colaborador(es) u otros Autores: | Daly S.A. McKenna C.J. Zhestkova N. Leal C. Breatnach F. Smelhaus V. Hung I.-J. Kowalczyk J. Ninane J. Mitchell T. Haigh C. |
| Fecha de publicación : | 2000 |
| Tipo de publicación: | Artículo |
| Formato: | |
| Identificador del Recurso : | 10.1080/08880010050120791 |
| Fuente: | Pediatric Hematology and Oncology 17(6):445 - 455 |
| URI : | http://repositorio.pediatria.gob.mx:8180/handle/20.500.12103/2025 |
| Idioma: | eng |
| Aparece en las colecciones: | Artículos |
Ficheros en este ítem:
No hay ficheros asociados a este ítem.
Los ítems de DSpace están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.